Hansoh Pharmaceutical (3692 HK): Innovative Drugs Drive 2024 Performance; Outlook Is Positive
Hansoh Pharma reported 33% YoY net profit growth on 21% YoY revenue growth in 2024. Revenue from innovative drugs grew 38% YoY and its proportion...
494 Views
BeiGene (6160 HK): Brukinsa Outpaces Competitor in 4Q US Sales; Solid Guidance for 2025
​BeiGene's Brukinsa sees significant growth in U.S. sales, surpassing Calquence for the first time, with 60%+ demand growth from expanded use in...
1.1k Views
Daiichi Sankyo (4568 JP): US Approval for Second ADC Drug to Drive Accelerated Growth
​FDA approves Daiichi Sankyo's Datroway for second-line treatment of breast cancer. Supported by AstraZeneca's commercialization expertise, the...
470 Views
Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well
WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.
806 Views
Upstream Bio Valuation Summary, DCF Analysis Suggests U.S. Business (Ex. COPD) Is Worth ~$1.8B
In my insight, I discuss DCF valuation for biotech company Upstream Bio ahead of upcoming IPO, which is expected to be priced in October
599 Views